Actuate Therapeutics Appoints BDO USA as New Auditor
Ticker: ACTU · Form: 8-K · Filed: Aug 19, 2024 · CIK: 1652935
| Field | Detail |
|---|---|
| Company | Actuate Therapeutics, Inc. (ACTU) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.000001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Actuate Therapeutics swapped auditors from CohnReznick to BDO USA, effective Aug 19.
AI Summary
Actuate Therapeutics, Inc. announced on August 19, 2024, a change in its certifying accountant. The company has appointed BDO USA, LLP as its new independent registered public accounting firm, replacing CohnReznick LLP. This change is effective immediately.
Why It Matters
A change in auditors can sometimes signal underlying issues or a strategic shift within a company, potentially impacting investor confidence.
Risk Assessment
Risk Level: low — This filing reports a routine change in the company's auditor, which typically carries low inherent risk.
Key Players & Entities
- Actuate Therapeutics, Inc. (company) — Registrant
- BDO USA, LLP (company) — New Certifying Accountant
- CohnReznick LLP (company) — Former Certifying Accountant
- August 19, 2024 (date) — Effective Date of Change
FAQ
Who is Actuate Therapeutics, Inc.'s new independent registered public accounting firm?
Actuate Therapeutics, Inc. has appointed BDO USA, LLP as its new independent registered public accounting firm.
Who was Actuate Therapeutics, Inc.'s previous independent registered public accounting firm?
Actuate Therapeutics, Inc.'s previous independent registered public accounting firm was CohnReznick LLP.
When was the change in certifying accountant effective?
The change in certifying accountant was effective as of August 19, 2024.
Did Actuate Therapeutics, Inc. have any disagreements with CohnReznick LLP that led to the change?
The filing does not state any disagreements between Actuate Therapeutics, Inc. and CohnReznick LLP that led to the change in auditors.
What is the Central Index Key (CIK) for Actuate Therapeutics, Inc.?
The Central Index Key (CIK) for Actuate Therapeutics, Inc. is 0001652935.
Filing Stats: 971 words · 4 min read · ~3 pages · Grade level 14.8 · Accepted 2024-08-19 17:25:36
Key Financial Figures
- $0.000001 — ch registered Common Stock, par value $0.000001 per share ACTU The Nasdaq Stock Mar
Filing Documents
- actuate_8k.htm (8-K) — 33KB
- actuate_ex1601.htm (EX-16.1) — 2KB
- 0001683168-24-005919.txt ( ) — 235KB
- actu-20240819.xsd (EX-101.SCH) — 3KB
- actu-20240819_def.xml (EX-101.DEF) — 26KB
- actu-20240819_lab.xml (EX-101.LAB) — 33KB
- actu-20240819_pre.xml (EX-101.PRE) — 22KB
- actuate_8k_htm.xml (XML) — 4KB
01. Changes in Registrant's Certifying Accountant
Item 4.01. Changes in Registrant's Certifying Accountant. On May 20, 2024, the partners and professional staff of KMJ Corbin & Company LLP ("KMJ"), the independent registered public accounting firm of Actuate Therapeutics, Inc. (the "Company"), joined Crowe LLP ("Crowe"), a public accounting, consulting and technology firm. The Company continued to receive services from KMJ until it resigned as the Company's independent registered public accounting firm on August 19, 2024. In connection with the resignation of KMJ, the Company's Audit Committee appointed Crowe to serve as the Company's independent registered public accounting firm effective August 19, 2024 for the fiscal year ending December 31, 2024. The reports of KMJ on the Company's consolidated financial statements for the two most recently completed fiscal years ended December 31, 2023 and 2022 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except that KMJ's audit report on the Company's consolidated financial statements as of and for the fiscal years ended December 31, 2023 and 2022 included an explanatory paragraph indicating that there was substantial doubt about the Company's ability to continue as a going concern. During the Company's two most recently completed fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through the date of resignation, there were no disagreements between the Company and KMJ on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of KMJ, would have caused KMJ to make reference to the subject matter of the disagreements in connection with its audit reports on the Company's consolidated financial statements. During the Company's two most recently completed fiscal years ended December 31, 2023 and 2022 and the subsequent interim p
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 16.1 Letter from KMJ Corbin & Company LLP 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Actuate Therapeutics, Inc. Date:August 19, 2024 By: /s/ Daniel M. Schmitt Name: Daniel M. Schmitt Title: President and Chief Executive Officer 3